Unhelpful information about adverse drug reactions: Kirin Tan and colleagues find that information about adverse drug reactions for commonly prescribed drugs is excessive, inconsistent, often poorly presented, and contaminated by symptoms commonly experienced in daily life. They suggest how we could do better

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Tan, Kirin ^a   Petrie, Keith J ^a   Faasse, Kate ^a   Bolland, Mark J ^a   Grey, Andrew ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ADVERSE DRUG REACTION; ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; HUMAN; INFORMATION DISSEMINATION; MEDICAL INFORMATION; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SYMPTOM;

EID: 84907205890     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g5019     Document Type: Article

References (33)

1. Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 2006;368:973-4.
2. Jin J, Sklar GE, Oh VMS, Li SC. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag 2008;4:269-86.
3. Fried TR, Tinetti ME, Towle V, O'Leary JR, Iannone L. Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. Arch Intern Med 2011;171:923-8.
4. Tosteson ANA, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16.
5. Grimes DA, Schulz KF. Nonspecific side effects of oral contraceptives: nocebo or noise? Contraception 2011;83:5-9.
6. Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA 2012;307:567-8.
7. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002;287:622-7.
8. Faasse K, Petrie KJ. The nocebo effect: patient expectations and medication side effects. Postgrad Med J 2013;89:540-6.
9. Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009;146:261-9.
10. Rief W. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf 2009;32:1041-56.
11. Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med 2007;4:1708-12.
12. Myers MG, Cairns JA, Singer J. The consent form as a possible cause of side effects. Clin Pharmacol Ther 1987;42:250-3.
13. Kaptchuk TJ, Stason WB, Davis RB, Legedza ART, Schnyer RN, Kerr CE, et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ 2006;332:391-7.
14. Wells RE, Kaptchuk TJ. To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent. Am J Bioeth 2012;12:22-9.
15. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9.
16. Law MR, Mintzes B, Morgan SG. The sources and popularity of online drug information: an analysis of top search engine results and web page views. Ann Pharmacother 2011;45:350-6.
17. Petrie K, Faasse K, Crichton F, Grey A. How common are symptoms? Results from a New Zealand national telephone survey. BMJ Open 2014;4:e005374.
18. De Langen J, van Hunsel F, Passier A, de Jong-van den Berg L, van Grootheest K. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf 2008;31:515-24.
19. Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med 2006;166:155-60.
20. Berry DC, Knapp P, Raynor DK. Provision of information about drug side-effects to patients. Lancet 2002;359:853-4.
21. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-7.
22. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
23. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Jr, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008;359:2195-207.
24. Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control. Int J Cardiol 2013;168:3573-9.
25. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014;21:464-74.
26. Ioannidis JPA. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 2009;169:1737-9.
27. Zorzela L, Golder S, Liu Y, Pilkington K, Hartling L, Joffe A, et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ 2014;348:f7668.
28. Goh SK, Yang KY, Koh JSB, Wong MK, Chua SY, Chua DTC, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89-B:349-53.
29. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:89-90.
30. Papanikolaou PN, Christidi GD, Ioannidis JPA. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. Can Med Assoc J 2006;174:635-41.
31. Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med 2009;150:516-27.
32. Horne R, Faasse K, Cooper V, Diefenbach MA, Leventhal H, Leventhal E, et al. The perceived sensitivity to medicines (PSM) scale:an evaluation of validity and reliability. Br J Health Psych 2013;18:18-30.
33. Joy TR, Monjed A, Zou GY, Hegele RA, McDonald CG, Mahon JL. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med 2014;160:301-10.